PeriMenoFriend® Effectiveness Research Abstract For Professionals
Real-World Effectiveness of PeriMenoFriend® in Supporting Women Through Perimenopause: User-Reported Outcomes from a Cross-Sectional Customer Survey
June 2026
Key Findings
- 94.6% of users rated PeriMenoFriend® effective in supporting them through perimenopause (n=352), with 44.3% rating it extremely effective and a combined negative rate of just 5.4%.
- A clear duration-response relationship was observed: extremely-effective ratings rose from 40.2% among users of under two months to 59.5% among those using it for four months or more, with the combined positive rate reaching 100% in the longest-duration group.
- Among the 70.2% of respondents who had never taken HRT, the combined positive rate was 97.6% — indicating strong benefit when PeriMenoFriend® is used as a non-hormonal approach.
- 88.9% reported relief in at least one symptom (mean 3.2 symptoms relieved per user), most commonly anxiety or mood swings (55.7%), hot flushes or night sweats (41.8%), and brain fog (39.2%).
- Onset of benefit was rapid: 75.8% of those reporting a timeframe noticed results within four weeks, and 89.6% within six weeks.
Background
Perimenopause — the transitional phase preceding menopause — is characterised by fluctuating hormones and a broad spectrum of physical and psychological symptoms, including mood disturbance, vasomotor symptoms, cognitive changes, fatigue, and sleep disruption. Many women seek non-hormonal options to manage these symptoms, whether by preference or because Hormone Replacement Therapy (HRT) is unsuitable or unwanted. PeriMenoFriend® is a nutritional supplement developed by DR.VEGAN®, formulated to support women specifically through the perimenopausal transition. This abstract reports real-world, user-reported outcomes from a cross-sectional customer feedback survey, including overall effectiveness, a duration-stratified analysis, symptom-level relief, time to benefit, and a comparison by HRT status.
Methods
A cross-sectional customer feedback survey was administered to DR.VEGAN® customers using PeriMenoFriend®, yielding 352 analysable responses. Respondents reported duration and consistency of use, overall effectiveness (four-point scale: extremely, somewhat, not so, not at all effective), time to first results, the specific symptoms from which they had experienced relief (multiple responses permitted across 16 defined symptoms), and HRT status. Effectiveness percentages are reported across all 352 respondents, none of whom were excluded, as every respondent provided a definitive effectiveness rating. A pre-specified duration-stratified analysis compared effectiveness across four usage-duration bands, and a subgroup analysis compared effectiveness by HRT status. Individual-level data were analysed for all responses.
Results
Cohort and adherence
Adherence was very high: 99.7% of respondents took the recommended dose daily (74.7%) or most days (25.0%), lending confidence that reported outcomes reflect consistent use. Duration of use spanned the full range, with 34.7% using the product for under two months, 43.5% for 2–3 months, 11.4% for 3–4 months, and 10.5% for four months or more. In terms of hormonal status, 70.2% had never taken HRT, 12.8% had previously taken HRT but no longer did, and 12.5% were current HRT users — meaning 83.0% were using PeriMenoFriend® as a non-hormonal approach at the time of survey.
Overall effectiveness. Of 352 respondents, 94.6% rated PeriMenoFriend® effective — 44.3% extremely effective and 50.3% somewhat effective. Only 4.0% rated it not so effective and 1.4% not at all effective, giving a combined negative rate of 5.4%. See Figure 1.
| Effectiveness rating | n | % of users |
|---|---|---|
| Extremely effective | 156 | 44.3% |
| Somewhat effective | 177 | 50.3% |
| Combined positive response | 333 | 94.6% |
| Not so effective | 14 | 4.0% |
| Not at all effective | 5 | 1.4% |
Duration-response relationship
A clear and consistent dose-response pattern emerged in the duration-stratified analysis. The extremely-effective rating rose monotonically with duration of use — from 40.2% at under two months to 42.5% at 2–3 months, 50.0% at 3–4 months, and 59.5% at four months or more — while the combined positive rate reached 100% in the longest-duration group. See Figure 2.
| Duration of use | n | Extremely effective | Combined positive |
|---|---|---|---|
| Under 2 months | 122 | 40.2% | 93.4% |
| 2–3 months | 153 | 42.5% | 93.5% |
| 3–4 months | 40 | 50.0% | 97.5% |
| 4+ months | 37 | 59.5% | 100.0% |
| Established users (≥2 months) | 230 | 46.5% | 95.2% |
Symptom relief profile
88.9% of respondents reported relief in at least one symptom, with a mean of 3.2 symptoms relieved per user and 62.5% reporting relief across three or more symptoms. Relief was concentrated in the psychological and vasomotor domains that most characterise perimenopause: anxiety or mood swings (55.7%), hot flushes or night sweats (41.8%), brain fog (39.2%), fatigue (33.2%), and poor sleep or insomnia (31.8%). See Figure 3.
| Symptom relieved | n (of 352) | % of users |
|---|---|---|
| Anxiety or mood swings | 196 | 55.7% |
| Hot flushes or night sweats | 147 | 41.8% |
| Brain fog | 138 | 39.2% |
| Fatigue | 117 | 33.2% |
| Poor sleep or insomnia | 112 | 31.8% |
| Joint pain | 80 | 22.7% |
| Bloating | 72 | 20.5% |
| Headaches or migraines | 65 | 18.5% |
| Lack of productivity | 48 | 13.6% |
| Low self-esteem | 46 | 13.1% |
| Low libido | 37 | 10.5% |
| Relief in at least one symptom | 313 | 88.9% |
Time to benefit
Onset of perceptible benefit was rapid. Of the 326 respondents who reported a specific timeframe, 75.8% first noticed results within four weeks, rising to 89.6% within six weeks. Only 5.2% required eight weeks or more. See Figure 4.
| Time to first results | n | % reporting a timeframe |
|---|---|---|
| 1–2 weeks | 70 | 21.5% |
| 2–3 weeks | 85 | 26.1% |
| 3–4 weeks | 92 | 28.2% |
| 4–6 weeks | 45 | 13.8% |
| 6–8 weeks | 17 | 5.2% |
| 8 weeks or more | 17 | 5.2% |
| Within 4 weeks (cumulative) | 247 | 75.8% |
Effectiveness by HRT status
A subgroup analysis by hormonal status showed that PeriMenoFriend® was rated effective by 97.6% of the 247 respondents who had never taken HRT (46.6% extremely effective), and by 87.6% of the 89 current or former HRT users. The very high positive rate among HRT-naïve users supports the role of PeriMenoFriend® as a non-hormonal option for women managing perimenopausal symptoms without hormone therapy.
Conclusions
In this large real-world feedback survey of 352 consistent users, PeriMenoFriend® demonstrated a high user-reported effectiveness rate (94.6%), broad-spectrum symptom relief (mean 3.2 symptoms per user), and rapid onset of benefit (75.8% within four weeks). A clear duration-response relationship was observed, with the extremely-effective rating rising from 40.2% to 59.5% across increasing durations of use and the combined positive rate reaching 100% beyond four months — underscoring the importance of sustained daily use for optimal benefit, consistent with the duration-dependent patterns observed in other DR.VEGAN® supplement evaluations. The particularly high positive rate among women who had never taken HRT (97.6%) supports the product’s positioning as a non-hormonal approach to perimenopausal symptom management. The principal limitations are the absence of a control group, reliance on self-reported outcomes, and a usage distribution weighted toward shorter durations; prospective, controlled studies with standardised symptom instruments and defined follow-up intervals would allow these real-world signals to be confirmed and the duration-response relationship to be characterised formally.
Keywords: PeriMenoFriend®, perimenopause, menopause, non-hormonal, HRT alternative, vasomotor symptoms, mood swings, brain fog, user-reported outcomes, duration-response, women’s health, nutritional supplement
Survey date: 2024–2025 | Respondents: N = 352 | Adherence: 99.7% daily or most days | Data type: Individual-level responses
Media enquiries: Please contact [email protected] | www.drvegan.com
Join our community of practitioners
Sign up for exclusive discounts for your clients, commission for you, free products to sample, priority access to latest research, expert webinars and events.
Join now